← Back to Search

Antifungal Agent

Itraconazole for Barrett's Esophagus

Phase 1
Recruiting
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8-12 months after study initiation
Awards & highlights

Study Summary

This trial will investigate if a drug can stop Barrett's esophagus from recurring after treatment, helping to prevent esophageal cancer and reduce complications.

Eligible Conditions
  • Barrett's Esophagitis with Dysplasia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8-12 months after study initiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8-12 months after study initiation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Itraconazole
Secondary outcome measures
Itraconazole
Effects of itraconazole on AKT pathway
Itraconazole
+2 more

Trial Design

2Treatment groups
Active Control
Group I: Itraconazole in capsule formActive Control1 Intervention
Participants in this arm will receive the capsule form of itraconazole
Group II: Itraconazole in solution formActive Control1 Intervention
Participants in this arm will receive the solution form of itraconazole

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
458 Previous Clinical Trials
169,078 Total Patients Enrolled
University of Texas, Southwestern Medical Center at DallasOTHER
14 Previous Clinical Trials
20,261 Total Patients Enrolled

Media Library

Itraconazole (Antifungal Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05609253 — Phase 1
Barrett's Esophagitis Research Study Groups: Itraconazole in capsule form, Itraconazole in solution form
Barrett's Esophagitis Clinical Trial 2023: Itraconazole Highlights & Side Effects. Trial Name: NCT05609253 — Phase 1
Itraconazole (Antifungal Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05609253 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential risks accompany the ingestion of Itraconazole capsules?

"With limited data substantiating its safety and efficacy, itraconazole in capsule form is assigned a score of 1 due to the Phase 1 trial status."

Answered by AI

What is the total enrollment figure for this research project?

"Affirmative. Clinicaltrials.gov reveals that this clinical trial is actively accruing patients; it was initially posted on September 14th 2022 and recently modified on November 1st 2022. Specifically, 10 individuals need to be recruited from one site for the study to move forward."

Answered by AI

Have applications been opened for the current trial?

"Affirmative. Clinicaltrials.gov indicates that this research project, which was originally published on September 14th 2022 and last amended November 1st 2022, is actively looking for 10 individuals from one medical centre."

Answered by AI
~4 spots leftby Mar 2025